Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × tariquidar × Clear all
NCT00082368 2017-08-17

PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

NCT00071058 2012-09-18

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 10 charts

Adrenal Cortex Neoplasms, Endocrine Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡